DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity.
Yang CG, Ciccolini J, Blesius A, Dahan L, Bagarry-Liegey D, Brunet C, Varoquaux A, Frances N, Marouani H, Giovanni A, Ferri-Dessens RM, Chefrour M, Favre R, Duffaud F, Seitz JF, Zanaret M, Lacarelle B, Mercier C.
Yang CG, et al. Among authors: lacarelle b.
Cancer Chemother Pharmacol. 2011 Jan;67(1):49-56. doi: 10.1007/s00280-010-1282-4. Epub 2010 Mar 5.
Cancer Chemother Pharmacol. 2011.
PMID: 20204365
Clinical Trial.